Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Plant specific N-glycans do not have proven adverse effects in humans

Nature Biotechnology volume 34, pages 706–708 (2016)Cite this article

Subjects

To the Editor:

Piron et al.1 recently reported that GlycoDelete can be used to synthesize correctly folded proteins that lack plant-specific N-glycan modifications in plant seeds. Previously, they reported a similar strategy to reduce N-glycan heterogeneity in mammalian proteins2. In their report the authors' noted concerns about the potential for immunogenicity and hypersensitivity owing to the presence of plant-specific glycosylation on proteins1. We contend that there are published data questioning the need to humanize glycosylation on plant-produced therapeutics.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Piron, R., Santens, F., De Paepe, A., Depicker, A. & Callewaert, N. Nat. Biotechnol. 33, 1135–1137 (2015).

    Article  CAS  PubMed  Google Scholar 

  2. Meuris, L. et al. Nat. Biotechnol. 32, 485–489 (2014).

    Article  CAS  PubMed  Google Scholar 

  3. Bardor, M. et al. Glycobiol. 13, 427–434 (2003).

    Article  CAS  Google Scholar 

  4. Landry, N. et al. PLoS One 5, e15559 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ward, B.J. et al. Vaccine 32, 6098–6106 (2014).

    Article  CAS  PubMed  Google Scholar 

  6. US Food and Drug Administration. Guidance for Industry, Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm250783.pdf (FDA, July 2013).

  7. Tekoah, Y. et al. Plant Biotechnol. J. 13, 1199–1208 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022458s003s006lbl.pdf (2014).

  9. Broomfield, A., Jones, S.A., Hughes, S.M. & Bigger, B. W. J. Inherit. Metab. Dis. doi:10.1007/s10545-016-9917-1 (2016).

  10. US Food and Drug Administration. Cerezyme (imiglucerase for injection): proposed text of the labeling of the drug. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf (FDA, March 2003).

  11. US Food and Drug Administration. Highlights of prescribing information for VPRIV. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022575s017lbl.pdf (FDA, April 2015).

  12. European Medicines Agency. European public assessment report (EPAR) summary for the public for Cerezyme. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000157/WC500024108.pdf

  13. Bosch, D., Castilho, A., Loos, A., Schots, A. & Steinkellner, H. Curr. Pharm. Des. 19, 5503–5512 (2013).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yoseph Shaaltiel & Yoram Tekoah are in the R&D Department, Protalix Ltd., Carmiel, Israel.,

    Yoseph Shaaltiel & Yoram Tekoah

Authors
  1. Yoseph Shaaltiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoram Tekoah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yoseph Shaaltiel or Yoram Tekoah.

Ethics declarations

Competing interests

The authors are employees of Protalix Ltd.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shaaltiel, Y., Tekoah, Y. Plant specific N-glycans do not have proven adverse effects in humans. Nat Biotechnol 34, 706–708 (2016). https://doi.org/10.1038/nbt.3556

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3556

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research